Department

neurology

Document Type

Article

Abstract

Summary The American Academy of Neurology published an evidence-based systematic review of randomized controlled trials using marijuana (Cannabis sativa) or cannabinoids in neurologic disorders. Several cannabinoids showed effectiveness or probable effectiveness for spasticity, central pain, and painful spasms in multiple sclerosis. The review justifies insurance coverage for dronabinol and nabilone for these indications. Many insurance companies already cover these medications for other indications. It is unlikely that the review will alter coverage for herbal marijuana. Currently, no payers cover the costs of herbal medical marijuana because it is illegal under federal law and in most states. Cannabinoid preparations currently available by prescription may have a role in other neurologic conditions, but quality scientific evidence is lacking at this time.

Medical Subject Headings

neurology

Publication Date

2015

Publication Title

Neurology: Clinical Practice

ISSN

2163-0402

Volume

5

Issue

4

First Page

344

Last Page

351

Digital Object Identifier (DOI)

10.1212/CPJ.0000000000000162

Download

Share

COinS